Zoe Van de Wyngaert
Overview
Explore the profile of Zoe Van de Wyngaert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
45
Citations
500
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fadel K, Siblany L, Mohty R, Stocker N, Suner L, Brissot E, et al.
Hemasphere
. 2025 Jan;
9(1):e70074.
PMID: 39872963
No abstract available.
2.
Stocker N, Alsuliman T, Corre E, Ricard L, Kaoui F, Coppo P, et al.
Clin Hematol Int
. 2025 Jan;
7(1):1-9.
PMID: 39764201
Individuals with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have a high risk of developing other malignancies (OMs). The development of OMs may be associated with the advanced...
3.
Alsuliman T, Psimaras D, Stocker N, Sestili S, Banet A, Van de Wyngaert Z, et al.
Bone Marrow Transplant
. 2024 Oct;
60(1):86-88.
PMID: 39420191
No abstract available.
4.
Ricard L, Cervera P, Stocker N, Corre E, Van de Wyngaert Z, Banet A, et al.
Front Immunol
. 2024 Jul;
15:1410638.
PMID: 38983865
Introduction: Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma characterized by a T follicular helper cell phenotype expressing PD-1 (programmed cell death-1). AITL exhibits a poor response to conventional...
5.
Siblany L, Stocker N, Ricard L, Brissot E, Dulery R, Banet A, et al.
J Clin Immunol
. 2024 Jun;
44(6):139.
PMID: 38822857
We evaluated the impact of early recovery of mucosal-associated invariant T cells (MAIT) and gamma-delta (γδ) T cells, especially Vδ2 T cells, on the clinical outcomes of 76 patients who...
6.
Paviglianiti A, Maia T, Gozlan J, Brissot E, Malard F, Banet A, et al.
Clin Hematol Int
. 2024 May;
6(1):26-38.
PMID: 38817703
Human herpesvirus type 6 (HHV6) reactivation after haploidentical hematopoietic cell transplantation (HCT) with post-transplant cyclophosphamide (PT-Cy) has been scarcely studied, especially when antithymocyte globulin (ATG) is added to the graft-versus-host...
7.
Van de Wyngaert Z, Romera-Martinez I, Chedeville C, Musiu P, Ikhlef S, Jonca B, et al.
Clin Hematol Int
. 2024 May;
6(2):46-50.
PMID: 38817306
We present the case of a dialyzed patient with relapsed IgA and lambda free light chain multiple myeloma treated with elranatamab. Despite end-stage renal impairment, the treatment with anti-B cell...
8.
Decaux O, Fontan J, Perrot A, Karlin L, Touzeau C, Schulmann S, et al.
Eur J Haematol
. 2024 May;
113(3):290-297.
PMID: 38712850
Background: IMAGE is a retrospective cohort study of patients enrolled in early access programs (EAPs) in France with relapsed/refractory multiple myeloma (RRMM) receiving isatuximab with pomalidomide and dexamethasone (Isa-Pd). Methods:...
9.
Malard F, Battipaglia G, Gaugler B, Siblany L, Van de Wyngaert Z, Bonnin A, et al.
Bone Marrow Transplant
. 2023 Aug;
58(11):1275-1278.
PMID: 37608072
No abstract available.
10.
Dulery R, Malard F, Brissot E, Banet A, Sestili S, Belhocine R, et al.
Bone Marrow Transplant
. 2023 Aug;
58(11):1215-1222.
PMID: 37596473
Post-transplant cyclophosphamide (PT-Cy) is effective for graft-versus-host disease (GVHD) prophylaxis, but it may cause dose-dependent toxicities, particularly in frail patients. Therefore, we compared the outcomes with a reduced PT-Cy total...